Drug Profile
Research programme: anti-cancer and anti-inflammatory biosimilars - Amgen/Simcere Pharmaceutical
Latest Information Update: 28 Oct 2021
Price :
$50
*
At a glance
- Originator Amgen
- Developer Amgen; Simcere Pharmaceutical Group
- Class Anti-inflammatories; Antineoplastics
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer; Inflammation
Most Recent Events
- 28 Oct 2021 No recent reports of development identified for preclinical development in Cancer in China (Parenteral)
- 28 Oct 2021 No recent reports of development identified for preclinical development in Inflammation in China (Parenteral)
- 26 Sep 2017 Amgen and Simcere Pharmaceutical Group agree to co-promote and co-develop four undisclosed biosimilars in China for Inflammation and Cancer